Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study

Abstract

Our results support the EMA warning, suggesting an increased risk of AP associated with MMI use. However, such an increase seems limited to the first months of MMI treatment. Moreover, in absolute terms, the probability of AP is low among patients, well below 1%.